Abstract 1041P
Background
Agonistic CD40 antibodies have been shown to promote anti-tumour T cell responses and promising activity has been observed in advanced solid tumours. Here we report the results of a multicenter, open-label study of YH003 + Toripalimab in dose escalation for pts with advanced solid tumours.
Methods
This was a phase I dose-escalation and expansion study. Part 1 was dose-escalation stage using an accelerated “3+3” design. The primary objective of Part 1 was safety and tolerability and to identify a maximum tolerated dose (MTD). Patients with advanced solid tumours received YH003 by IV administration Q3W as monotherapy at 0.03, 0.1, 0.3, 1.0 and 3.0 mg/kg for the first cycle (21 days), then in combination with fixed-dose Toripalimab at 240 mg Q3W from cycle 2. Patients tolerating treatment and deriving benefit could continue treatment for up to 1 year.
Results
Between 29 Jul 2020 and 26 May 2022, 20 pts were treated in Part 1. A DLT (dose-limiting toxicity) was observed at 1.0 mg/kg dose level (grade 3 transaminitis) in 1 pt. The MTD was not reached. Among Part 1 pts, 13 (65%) had any grade treatment related adverse events (TRAEs). The most common (≥ 10%) TRAEs were infusion related reactions, pyrexia, fatigue, nausea, elevated AST/ALT. No Grade 3-5 TRAEs and treatment-related SAEs occurred. 8 pts had received prior immunotherapy (PD-1/PD-L1 or PD-1+CTLA-4). Among 16 pts assessable for response, 1 pt achieved a complete response (CR), another pt achieved a partial response (PR) and 3 pts achieved stable disease (SD). A pt with anti-PD1/anti-CTLA4 refractory ocular melanoma with liver metastases (0.1 mg/kg dose level) achieved PR at the first tumour assessment in week 10 and ultimately a CR after nearly 2 years of study treatment. YH003 was well tolerated up to 3.0 mg/kg dose levels when combined with Toripalimab. Combining safety and preliminary efficacy data, the recommended dose of YH003 for part 2 was 0.3 mg/kg.
Conclusions
YH003 was well tolerated up to 3.0 mg/kg dose levels when combined with Toripalimab, and 0.3mg/kg was deemed the RP2D. YH003 has shown encouraging antitumour activity in patients with advanced solid tumours.
Clinical trial identification
NCT04481009.
Editorial acknowledgement
Legal entity responsible for the study
Eucure (Beijing) Biopharma Co., Ltd.
Funding
Eucure (Beijing) Biopharma Co., Ltd.
Disclosure
B. Markman: Financial Interests, Personal, Advisory Board: Amgen, MSD, Bristol Myers Squibb, BeiGene, AstraZeneca. J. Coward: Financial Interests, Institutional, Research Funding: AstraZeneca. M. Millward: Financial Interests, Personal, Advisory Board: BeiGene Australia Pty Ltd, Bristol Myers Squibb Australia Pty Ltd, AstraZeneca Australia Pty Ltd, The Limbic, Eli Lilly Australia Pty Ltd, IQVIA Australia Pty Ltd, Amgen Australia Pty Ltd, Merck Pte Ltd, Pfizer Australia Pty Ltd, Guardant Health, Roche Products Pty Ltd; Financial Interests, Personal, Full or part-time Employment, Employee: University of Western Australia; Financial Interests, Personal, Other, Consultant: Linear Clinical Research; Financial Interests, Institutional, Local PI, Trial payments to Institution: Bristol Myers Squibb, Genentech/Roche, BeiGene, Eli Lilly, Albion Laboratories, Akeso Biopharma, AbbVie, Five Prime Therapeutics, Dizal Pharma, Maxinovel, Amgen, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Rely Therapeutics, GenFleet Therapeutics, Vivace Therapeutics, Eucure Biopahrma, InventisBio, Cullinan Oncology, Tyra Biosciences, Axelia Oncology; Non-Financial Interests, Other, Scientific Advisory Committee member: Thoracic Oncology Group Australasia. All other authors have declared no conflicts of interest.
Resources from the same session
1079TiP - A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Presenter: Shiraj Sen
Session: Poster session 19
1080TiP - An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Presenter: Vladimir Galvao
Session: Poster session 19
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19